Clinical Trials Browser

Phase 2 × aumolertinib × 1 year × Clear all

NCT06951464 2025-07-23

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung